The trial reached equally its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically important and outstanding enhancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH in comparison to placebo.oneProgram monitoring of serum c